Gabrielis Kundrotas

Dr. Gabrielis Kundrotas

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
GKGabrielis Kundrotas
Gabrielis Kundrotas
EGEvelina Gasperskaja
Evelina Gasperskaja
GSGrazina Slapsyte
Grazina Slapsyte
ZGZivile Gudleviciene
Zivile Gudleviciene
JKJan Krasko
Jan Krasko
RLRegina Liudkeviciene
Regina Liudkeviciene
Identity, proliferation capacity, genomic stability and novel senescence markers of mesenchymal stem cells isolated from low volume of human bone marrow

15 November 2023 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
PBPaola Bisaccia
Paola Bisaccia
FMFabio Magarotto
Fabio Magarotto
SDStefania D’aGostino
Stefania D’aGostino
ADArben Dedja
Arben Dedja
SBSilvia Barbon
Silvia Barbon
Michela PozzobonMichela Pozzobon
Michela Pozzobon
Oxidative stress and fibrosis are important stress responses that characterize bronchopulmonary dysplasia (BPD), a disease for which only a therapy but not a cure has been developed. In this work, we investigated the effects of mesenchymal stromal cells-derived extracellular vesicles (MSC-EVs) on lung and brain compartment in an animal model of hyperoxia-induced BPD. Rat pups were intratracheally injected with MSC-EVs produced by human umbilical cord-derived MSC, following the Good Manufacturing Practice-grade (GMP-grade). After evaluating biodistribution of labelled MSC-EVs in rat pups left in normoxia and hyperoxia, oxidative stress and fibrosis investigation were performed. Oxidative stress protection by MSC-EVs treatment was proved both in lung and in brain. The lung epithelial compartment ameliorated glycosaminoglycan and surfactant protein expression in MSC-EVs-injected rat pups compared to untreated animals. Pups under hyperoxia exhibited a fibrotic phenotype in lungs shown by increased collagen deposition and also expression of profibrotic genes. Both parameters were reduced by treatment with MSC-EVs. We established an in vitro model of fibrosis and another of oxidative stress, and we proved that MSC-EVs suppressed the induction of αSMA, influencing collagen deposition and protecting from the oxidative stress. In conclusion, intratracheal administration of clinical-grade MSC-EVs protect from oxidative stress, improves pulmonary epithelial function, and counteracts the development of fibrosis. In the future, MSC-EVs could represent a new cure to prevent the development of BPD.

1 June 2012 in Acta medica Lituanica
Verified
Journal Article
Open access
PDF file
GKGabrielis Kundrotas
Gabrielis Kundrotas
Human mesenchymal stem cells (MSCs) are widely used for treatment of various diseases. Clinical applications require large quantities of MSCs, therefore these cells must be expanded in the culture system. It is believed that contamination of MSC cultures with fibroblasts may lead to the decrease of the stem cell differentiation potential. Moreover, such stem cell preparations are potentially unsafe to use for clinical applications since a few fibroblasts can become tumorigenic. Therefore, there is a need to separate MSCs from fibroblasts. However, studies show that MSCs and fibroblasts have much in common. These two types of cells share such properties as identical spindle-like morphology, plastic adherence and the same expression of most surface antigens. The aim of this review article is to analyze the literature on the similarities and differences between the MSCs and fibroblasts, particularly in the expression of cell surface markers in order to determine which could be used for quick separating of MSCs from fibroblasts. Interestingly, the results of recent studies suggest that the use of CD10, CD26, CD106, CD146 and ITGA11 could be helpful for the discrimination of MSCs from fibroblasts. Identification and elimination of fibroblasts from MSC cultures could improve the MSC yield and differentiation potential and also prevent possible tumor formation after MSC transplantation.

8 October 2014 in Open Medicine
Verified
Journal Article
Open access
ŽGŽivilė Gudlevičienė
Živilė Gudlevičienė
GKGabrielis Kundrotas
Gabrielis Kundrotas
RLRegina Liudkeviciene
Regina Liudkeviciene
JRJelena Rascon
Jelena Rascon
MJMarcin Jurga
Marcin Jurga
Background. Mesenchymal stem cells (MSCs) are currently exploited in numerous clinical trials to investigate their potential in immune regulation, hematopoesis or tissue regeneration. The most common source of MSCs for clinical use is human bone marrow. To generate sufficient numbers of cells relevant to clinical use in most cases the high volumes (20-50 ml) of bone marrow aspirates are taken. Methods. In this pilot study, 8 healthy bone marrow donors were included. Two different MSC extraction methods were evaluated: MSCs extraction from 60 ml of bone marrow using density gradient and MSCs extraction from 6 ml using red blood cell (RBC) lysis. Results. Our results showed that after RBC lysis the efficient amount of human MSCs can be isolated from 10 times less bone marrow volume (6 ml). Moreover, using small volume of bone marrow the adequate therapeutical dose of MSCs could be achieved during similar period of time (3-4 weeks). In conclusion, we have shown that MSCs isolation using RBC lysis is an effective and more advantageous method in comparison to standard MSCs isolation using density-gradient. Using RBC lysis from small volume of bone marrow the same amount of MSCs were obtained as usually using large volume and density-gradient.

13 March 2019 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
GKGabrielis Kundrotas
Gabrielis Kundrotas
VKVitalijus Karabanovas
Vitalijus Karabanovas
MPMarijus Pleckaitis
Marijus Pleckaitis
MJMarina Juraleviciute
Marina Juraleviciute
SSSimona Steponkiene
Simona Steponkiene
RRRicardas Rotomskis
Ricardas Rotomskis
Human mesenchymal stem cells (MSCs) have drawn much attention in the field of regenerative medicine for their immunomodulatory and anti-inflammatory effects. MSCs possess specific tumor-oriented migration and incorporation highlighting the potential for MSCs to be used as an ideal carrier for anticancer agents. Bone marrow is the main source of MSCs for clinical applications. MSCs tracking in vivo is a critical component of the safety and efficacy evaluation of therapeutic cell products; therefore, cells must be labeled with contrast agents to enable visualization of the MSCs migration in vivo. Due to their unique properties, quantum dots (QDs) are emerging as optimal tools in long-term MSC optical imaging applications. The aim of this study was to investigate the uptake dynamics, cytotoxity, subcellular and extracellular distribution of non-targeted carboxylated quantum dots in human bone marrow MSCs at different cell growing densities. QDs had no negative impact on MSC viability throughout the experiment and accumulated in all observed cells efficiently; however, in some MSCs QDs induced formation of lipid droplets. At low cell growing densities QDs distribute within MSCs cytoplasm already after 1 h of incubation reaching saturation after 6 h. After 24 h QDs localize mainly in the perinuclear region of the cells in endosomes. Interestingly, in more confluent culture QDs localize mostly outside MSCs. QDs abundantly mark MSC long filopodia-like structures attaching neighboring cells. At high cell density cultivation, we for the first time demonstrated that carboxylated QDs localize in human bone marrow MSC extracellular matrix. Moreover, we observed that average photoluminescence lifetime of QDs distributed in extracellular matrix are longer than lifetimes of QDs entrapped in endocytic vesicles; thus, for the first time showing the possibility to identify and distinguish localization of QDs in various extracellular and intracellular structures using fluorescence-lifetime imaging microscopy without additional staining assays. Carboxylated QDs can be used as nonspecific and effective dye for staining of human bone marrow MSCs and their specific extracellular structures. These results are promising in fundamental stem cell biology as well as in cellular therapy, anticancer drug delivery and tissue engineering.

1 January 2014 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
PTPaulius Tamosiunas
Paulius Tamosiunas
RPRasa Petraitytė-Burneikienė
Rasa Petraitytė-Burneikienė
RLRita Lasickienė
Rita Lasickienė
AAArtiomas Akatov
Artiomas Akatov
GKGabrielis Kundrotas
Gabrielis Kundrotas
KSKęstutis Sasnauskas
Kęstutis Sasnauskas
Porcine parvovirus (PPV) is a widespread infectious virus that causes serious reproductive diseases of swine and death of piglets. The gene coding for the major capsid protein VP2 of PPV was amplified using viral nucleic acid extract from swine serum and inserted into yeastSaccharomyces cerevisiaeexpression plasmid. Recombinant PPV VP2 protein was efficiently expressed in yeast and purified using density gradient centrifugation. Electron microscopy analysis of purified PPV VP2 protein revealed the self-assembly of virus-like particles (VLPs). Nine monoclonal antibodies (MAbs) against the recombinant PPV VP2 protein were generated. The specificity of the newly generated MAbs was proven by immunofluorescence analysis of PPV-infected cells. Indirect IgG ELISA based on the recombinant VLPs for detection of PPV-specific antibodies in swine sera was developed and evaluated. The sensitivity and specificity of the new assay were found to be 93.4% and 97.4%, respectively. In conclusion, yeastS. cerevisiaerepresents a promising expression system for generating recombinant PPV VP2 protein VLPs of diagnostic relevance.